This valuable tool will help doctors prevent atherosclerosis, a life-threatening complication of lupus.
News & Stories
Lupus Foundation of America medical director Dr. Joan Merrill discusses a recently completed a study that may help to improve the design for future lupus clinical trials and secure approval of new safe and more tolerable treatments for lupus.
A team of lupus researchers has identified a potential new biomarker that may be helpful in determining whether a person with lupus is at risk for developing organ damage.
The researchers hoped to learn about the genetic contributions to lupus susceptibility and how this might relate to specific lupus-related phenotypes, such as the presence of specific autoantibodies.
The researchers hoped to learn about the relationship among hsCRP, lupus disease activity, and the risk of cardiovascular disease in individuals with lupus.
To help identify biomarkers of early lupus, the researchers aimed to establish a relationship between levels of specific autoantibodies and the evolution of clinical signs of lupus over time.
A study published in a recent issue of the journal Lupus characterizes a new potential biomarker of fatigue in people with lupus.
People with lupus may experience chronic fatigue, the exact causes of which are yet to be fully understood. There are a number of different energy-producing metabolic processes that may be affected in people with lupus.
This study examined the relationship between fluctuating levels of vitamin D during different seasons, characterized by differing amounts of light exposure, while patients experienced lupus flares.
The researchers hoped to learn about the relationship between type I interferon and premature heart disease risk among people with lupus.
The use of lupus biomarkers, such as those present in the blood or urine, to help predict and/or manage lupus nephritis over time could be very useful. The results of this study highlight the potential feasibility of using lupus biomarkers to differentiate between acute and chronic kidney disease activity-related changes.
The development of a single test that can simultaneously measure several different autoantibodies important in lupus could be important and useful.
The Lupus Foundation of America is excited to see increased media attention surrounding lupus biomarkers, which are useful for diagnosing a disease.
The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.
Biomarkers are very much in the news today, in stories about how to determine who is at risk for a disease or condition, or the ways in which a group or population is reacting to a particular treatment. They also play a role in the development of new medications.
The researchers hoped to learn about whether a protein in the blood called C4d could serve as an indicator of lupus nephritis activity in people with lupus.
The researchers hoped to identify a set of microRNAs common to three different strains of mice that have been genetically modified in different ways to have lupus, making it more likely that something similar to these microRNAs might be found in substantial percentages of people.
Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.
The researchers studied the relationship between anti-NR2A antibodies and different aspects of lupus, especially whether there might be a relationship between these antibodies and NPSLE in patients from Japan.
The researchers hoped to learn whether people with lupus kidney involvement from different races shared the same set of microRNAs.
Current treatments for lupus nephritis in children are toxic and sometimes ineffective. New tests for proteins that might be abnormal in lupus nephritis could help make the diagnosis earlier and might also point to new ways of treating the disease.
The researchers hoped to learn whether measurement of C3d and C4d would be a more accurate way to test for lupus disease activity when measured while attached to a red blood cell than when they are freely circulating in the blood.
The researchers hoped to find out if levels of a protein called TWEAK in samples of the urine or blood could be used to diagnose lupus nephritis.
The researchers wanted to find out whether the amount of leptin, adiponectin, or ghrelin in children with lupus might be different than in children without lupus.